Anti-BCL2L12 Monoclonal Antibody for WB, IHC-P, IP, ELISA - Q9HB09

Core Product Specifications and Parameters

Biological Background: BCL2L12 Function and Localization

• BCL2L12, also known as Bcl-2-related proline-rich protein (BPR), belongs to the Bcl-2 family of apoptosis regulators.
• The gene produces multiple isoforms through alternative splicing, with isoform 2 exhibiting predominant expression in skeletal muscle.
• Widely expressed in human tissues, with higher levels in breast, thymus, prostate, fetal liver, colon, placenta, pancreas, small intestine, spinal cord, kidney, and bone marrow; lower levels in many other tissues.
• Functional keywords from UniProt include apoptosis, methylation, and phosphoprotein, suggesting regulatory roles in programmed cell death and post-translational modifications.
• The protein is subject to methylation and phosphorylation, which may modulate its activity and interactions.
• Proteomics identification confirms its expression in human cells, supporting its relevance in cellular homeostasis.

Experimental Guidance and Technical Tips

• The immunogen corresponds to amino acids 200–250 of human BCL2L12, a region that may be conserved across isoforms; verify reactivity for your specific isoform of interest.
• For Western blot, the antibody detects a band at approximately 37 kDa, which may represent full-length or post-translationally modified BCL2L12; consider using appropriate controls to confirm specificity.
• In immunohistochemistry (IHC-P), optimize antigen retrieval conditions for your tissue type, as BCL2L12 expression can vary among different tissues.
• For immunoprecipitation (IP), test antibody compatibility with native BCL2L12 under non-reducing conditions to preserve interaction partners.
• When using ELISA, pair with a carefully selected detection antibody to ensure sandwich format compatibility.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, including validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents. For BCL2L12 and other apoptosis-related targets, our comprehensive sourcing solutions support every stage from concept to clinic, helping you accelerate development with reliable, ready-to-use raw materials.